Photo from wikipedia
Opicapone (Ongentys) is a new once‐daily catechol‐O‐methyl transferase (COMT) inhibitor with a long duration of action allowing once‐daily dosing, licensed for adjunctive therapy in adults with Parkinson's disease and end‐of‐dose… Click to show full abstract
Opicapone (Ongentys) is a new once‐daily catechol‐O‐methyl transferase (COMT) inhibitor with a long duration of action allowing once‐daily dosing, licensed for adjunctive therapy in adults with Parkinson's disease and end‐of‐dose motor fluctuations. This article discusses its indications, efficacy and adverse effects.
Keywords:
adjunctive therapy;
opicapone daily;
parkinson disease;
therapy parkinson;
daily adjunctive
Journal Title: Prescriber
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Prescriber
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!